Although there was no correlation between responders to immunotherapy (CR+PR) and Fas expression, patients with PD after immunotherapy expressed Fas more frequently in primary tumours than other patients (CR+PR+NC) (P=0.0484) (Table 3). This evidence concerns the gene FAS and neoplasm.